Comparative Pharmacology
Head-to-head clinical analysis: DIFICID versus XIFAXAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFICID versus XIFAXAN.
DIFICID vs XIFAXAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, leading to RNA synthesis inhibition and cell death. It is bactericidal against Clostridioides difficile and has minimal systemic absorption.
Rifaximin is a non-systemic, gut-selective antibiotic that inhibits bacterial RNA synthesis by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase, thereby reducing bacterial overgrowth and altering gut microbiota composition.
200 mg (tablet) orally twice daily for 10 days.
550 mg orally twice daily for traveler's diarrhea; 550 mg orally three times daily for hepatic encephalopathy.
None Documented
None Documented
11.7 hours (terminal half-life in healthy subjects); supports twice-daily dosing.
The terminal elimination half-life for rifaximin after oral administration ranges from 1.8 to 10 hours, with a mean of approximately 6 hours. The half-life is extended in hepatic impairment due to reduced clearance, and no dosage adjustment is recommended for renal impairment.
Fecal (primarily as unchanged drug, ~44% of dose); renal (~1.6% unchanged, <1% as metabolites); biliary (minor).
Rifaximin is primarily eliminated unchanged in feces via biliary excretion (approximately 97% of an oral dose). Renal excretion of unchanged drug accounts for <0.4% of the dose. Fecal elimination is the major route.
Category C
Category C
Antibiotic
Antibiotic